Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
about
Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrierPeripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's diseaseAβ peptide fibrillar architectures controlled by conformational constraints of the monomerAn anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 miceIdentification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosisPyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's diseaseAlzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination.Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated AβOverexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.Targets for AD treatment: conflicting messages from γ-secretase inhibitorsGlutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanismsDevelopment of a new DNA vaccine for Alzheimer disease targeting a wide range of aβ species and amyloidogenic peptidesAge-related changes of neuron numbers in the frontal cortex of a transgenic mouse model of Alzheimer's disease.Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer diseasePyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degusAlzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias.Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits.Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse modelspGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models.Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy.Expression of the Alzheimer's Disease Mutations AβPP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs.Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
P2860
Q27332086-84D249A9-38BC-4185-99A4-511C237154D4Q27437619-8710E80E-CBC5-4ADD-AC73-A6542E34BE07Q28744420-FE39B3BD-D460-43F7-A67A-68AFA5CDDC7AQ30316057-66DA4522-969E-454E-BFDE-03235F5E203CQ30497751-D141406E-BF6C-4F03-805D-B2D8CD8D564EQ30512697-6948A269-E809-4B24-A8A0-BE8053F149C1Q33624303-645DAF47-393D-4189-A5F9-A4475DE11ECBQ33786789-81182AD3-BA5A-45B4-A4A6-BE745B65DFD2Q33942884-60353308-477A-46E6-9737-34736BA7F439Q34348316-5A1D6527-2E11-42BC-8317-4A302BF9F099Q34481815-2ACA15D1-EEF4-4467-A6FB-6CBE09861C0AQ34575806-86BF6A4F-4757-4A3F-94A2-278DD88AB083Q34792043-1F7CB456-699E-4E29-A821-2C143E2A2E88Q34995785-B9FDA99E-D8C0-4BED-B2E8-509623811603Q35005432-4E2EE011-9EC3-42FF-AF2B-F4100CF2F023Q35161238-EAC0357A-42F7-4FF4-95DD-05B4FDB37DC5Q35246412-4C4EC6C1-941C-43B6-A53C-2B8696AA3B62Q35604177-46033DD5-AEAD-4DF6-A4D3-557307105D46Q35660682-C8BF3DD6-457C-463F-8600-4D63E24D83E8Q35679473-675FD136-E7D2-4D66-B15C-EB91AC0A8A5DQ35743990-B3E2AA4B-3CDC-44BD-90FD-FF31B3111F5EQ36340365-739AE07C-3497-47B7-95E8-1F4EC6B6C63BQ36356545-3094E490-323A-4AA3-8E2E-51F755691FDCQ36605288-5F41D8C2-0AD5-44F7-86E2-47E41946A2AEQ36984142-BA470F85-A875-423B-B970-CC6A9F073CD4Q37043304-382A1FE6-6C26-46C4-B03A-417B39C296AFQ37062829-CFA6C447-2FF5-4903-92B0-0A987CDDF1BBQ37322106-8857EAD7-8081-4D73-BDAE-9B7B9E830381Q37485472-D47C16D6-B312-4A7F-838D-0B4B7DFA5318Q38016898-845E87F9-4F9F-4FE7-A2FE-A191CD4F7522Q38118901-C9630698-3806-4515-9774-8FCE26CA5A7FQ38176899-F109ACEC-1FDD-4406-9CEE-4ABE43673768Q42278922-2A4DB62F-5684-463F-B9E0-89423DEE8A9DQ46335422-96F59A3C-5049-481B-BC07-4D0DDAC489B5Q46348872-CE63D436-91F7-486F-8684-CDD19B672E9FQ46902534-D43F2666-2244-444A-A3C6-617390205979Q48562250-5B90737C-9162-44B3-A339-943592466C69Q50690253-AB9019E2-6EC6-4B75-AE54-FFFAD3B89ABEQ53311356-8955DEEF-B147-4F3F-BE9B-8A4D38B700C6Q55021292-5A3AC169-9B6C-4CC8-B68A-D22D4E369EB9
P2860
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@en
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@nl
type
label
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@en
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@nl
prefLabel
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@en
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@nl
P2093
P2860
P1476
Pyroglutamate Abeta pathology ...... ial Alzheimer's disease cases.
@en
P2093
Andrea Marcello
Anja Harmeier
David L Brody
Hannu Kalimo
Lars Lannfelt
Oliver Wirths
Paul J Lucassen
Sadim Jawhar
Thomas A Bayer
Thomas Esparza
P2860
P2888
P356
10.1007/S00702-009-0314-X
P577
2009-10-13T00:00:00Z